Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?
作者信息
Patoulias Dimitrios, Papadopoulos Christodoulos, Katsimardou Alexandra, Toumpourleka Maria, Doumas Michael
机构信息
Second Propedeutic Department of Internal Medicine, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
Third Department of Cardiology, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
出版信息
J Clin Hypertens (Greenwich). 2020 Dec;22(12):2389-2390. doi: 10.1111/jch.14079. Epub 2020 Oct 15.
Abstract
摘要
相似文献
1
Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?钠-葡萄糖协同转运蛋白2抑制剂与动脉僵硬度：类效应还是药物效应？
J Clin Hypertens (Greenwich). 2020 Dec;22(12):2389-2390. doi: 10.1111/jch.14079. Epub 2020 Oct 15.
2
Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.将二肽基肽酶-4 抑制剂转换为钠-葡萄糖共转运蛋白 2 选择性抑制剂托格列净可改善 2 型糖尿病患者的动脉僵硬度：一项初步研究。
Curr Vasc Pharmacol. 2019;17(4):411-420. doi: 10.2174/1570161116666180515154555.
3
Luseogliflozin: first global approval.鲁格列净：全球首次获批。
Drugs. 2014 Jun;74(8):945-50. doi: 10.1007/s40265-014-0230-8.
4
Randomized, "head-to-head" studies comparing different SGLT2 inhibitors are definitely needed.绝对需要进行比较不同SGLT2抑制剂的随机“头对头”研究。
J Clin Hypertens (Greenwich). 2020 Dec;22(12):2391-2392. doi: 10.1111/jch.14077. Epub 2020 Oct 21.
5
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净可控制血糖，降低主动脉僵硬度、肾电阻率指数和肾脏损伤。
Cardiovasc Diabetol. 2018 Jul 30;17(1):108. doi: 10.1186/s12933-018-0750-8.
6
Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.恩格列净治疗3个月对2型糖尿病患者动态血压和动脉僵硬度的影响。
Ann Afr Med. 2021 Apr-Jun;20(2):154-155. doi: 10.4103/aam.aam_19_20.
7
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.恩格列净如何改善 2 型糖尿病患者的动脉僵硬度？临床试验的亚组分析。
Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8.
8
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖共转运蛋白-2 抑制剂及其联合应用对 2 型糖尿病患者内皮糖萼、动脉功能和心肌做功指数的影响：12 个月治疗后的结果。
J Am Heart Assoc. 2020 May 5;9(9):e015716. doi: 10.1161/JAHA.119.015716. Epub 2020 Apr 24.
9
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.达格列净通过抑制 SGLT2 改善 2 型糖尿病小鼠的全身性血管功能障碍并改变肠道微生物群。
Cardiovasc Diabetol. 2018 Apr 27;17(1):62. doi: 10.1186/s12933-018-0708-x.
10
Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.钠葡萄糖协同转运蛋白2抑制剂鲁格列净在2型糖尿病管理中的应用：药物安全性评价
Expert Opin Drug Saf. 2017 Oct;16(10):1211-1218. doi: 10.1080/14740338.2017.1359252. Epub 2017 Aug 18.
引用本文的文献
1
Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.恩格列净和达格列净对伴有心血管合并症的 2 型糖尿病患者动态动脉僵硬度的影响：一项前瞻性观察研究。
Medicina (Kaunas). 2022 Aug 27;58(9):1167. doi: 10.3390/medicina58091167.
2
Randomized, "head-to-head" studies comparing different SGLT2 inhibitors are definitely needed.绝对需要进行比较不同SGLT2抑制剂的随机“头对头”研究。
J Clin Hypertens (Greenwich). 2020 Dec;22(12):2391-2392. doi: 10.1111/jch.14077. Epub 2020 Oct 21.
本文引用的文献
1
Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective?解读VERTIS-CV试验结果：“类效应”观点是否就此终结？
J Diabetes. 2020 Dec;12(12):942-945. doi: 10.1111/1753-0407.13105. Epub 2020 Sep 4.
2
Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.利格列汀对 2 型糖尿病患者动脉功能的影响：多中心、探索性的 LUSCAR 研究。
J Clin Hypertens (Greenwich). 2020 Sep;22(9):1585-1593. doi: 10.1111/jch.13988. Epub 2020 Aug 18.
3
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖共转运蛋白-2 抑制剂及其联合应用对 2 型糖尿病患者内皮糖萼、动脉功能和心肌做功指数的影响：12 个月治疗后的结果。
J Am Heart Assoc. 2020 May 5;9(9):e015716. doi: 10.1161/JAHA.119.015716. Epub 2020 Apr 24.
4
Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors.动脉僵硬度测量在心血管疾病、糖尿病及其并发症中的预后价值：钠-葡萄糖共转运蛋白-2 抑制剂的潜在作用。
J Clin Hypertens (Greenwich). 2020 Apr;22(4):562-571. doi: 10.1111/jch.13831. Epub 2020 Feb 14.
5
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.达格列净急性改善 2 型糖尿病患者的内皮功能障碍，降低主动脉僵硬度和肾血管阻力指数：一项初步研究。
Cardiovasc Diabetol. 2017 Oct 23;16(1):138. doi: 10.1186/s12933-017-0621-8.
6
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.选择性钠-葡萄糖协同转运蛋白2抑制剂恩格列净对2型糖尿病患者血管功能和中心血流动力学的影响。
Circulation. 2017 Sep 19;136(12):1167-1169. doi: 10.1161/CIRCULATIONAHA.117.029529.
7
Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects.主动脉脉搏波速度可改善心血管事件预测：来自 17635 名受试者的前瞻性观察性数据的个体参与者荟萃分析。
J Am Coll Cardiol. 2014 Feb 25;63(7):636-646. doi: 10.1016/j.jacc.2013.09.063. Epub 2013 Nov 13.
8
Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.动脉僵硬度预测心血管事件和全因死亡率：系统评价和荟萃分析。
J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi: 10.1016/j.jacc.2009.10.061.
Zotero 插件